Open AccessImproved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Disease
Author(s) -
Laura Bauman,
Yan Xiong,
Tomoyuki Mizuno,
Philip Minar,
Tsuyoshi Fukuda,
Min Dong,
Michael J. Rosen,
Alexander A. Vinks
Publication year - 2019
Publication title -
inflammatory bowel diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.932
H-Index - 146
eISSN - 1536-4844
pISSN - 1078-0998
DOI - 10.1093/ibd/izz143
Subject(s) - medicine , infliximab , inflammatory bowel disease , population , confidence interval , erythrocyte sedimentation rate , dosing , pharmacokinetics , therapeutic drug monitoring , trough concentration , receiver operating characteristic , trough level , area under the curve , gastroenterology , disease , transplantation , environmental health , tacrolimus
Many pediatric patients with inflammatory bowel disease (IBD) lose response to infliximab (IFX) within the first year, and achieving a minimal target IFX trough concentration is associated with higher remission rates and longer durability. Population pharmacokinetic (PK) modeling can predict trough concentrations for individualized dosing. The object of this study was to refine a population PK model that accurately predicts individual IFX exposure during maintenance therapy using longitudinal real-practice data.